Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridGökyer, Ali/0000-0002-1653-6155
dc.authorwosidErdogan, Bulent/AAA-9781-2021
dc.authorwosidKurt, Nazmi/JFA-8132-2023
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidGökyer, Ali/AAQ-5700-2020
dc.contributor.authorGokyer, Ali
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorKostek, Osman
dc.contributor.authorHacioglu, Muhammet Bekir
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorKula, Osman
dc.contributor.authorKurt, Nazmi
dc.date.accessioned2024-06-12T10:58:25Z
dc.date.available2024-06-12T10:58:25Z
dc.date.issued2020
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives Contrast nephropathy risk has been increasing in cancer patients. Nephrotoxic side effects of anti-vascular endothelial growth factor/receptor (anti-VEGF/R) drugs used in oncologic treatment are also prominent. The purpose of this study was to identify the possible association among anti-VEGF/R drugs use and development of the contrast-induced nephropathy (CIN) in patients with cancers. Methods A total of 92 patients were included in this prospective cross-sectional study. Patients whose glomerular filtration rate (GFR) of < 50 ml/min, hemoglobin of < 10 g/dl, and eastern cooperative oncology group (ECOG) score of >= 2 and had received nephrotoxic drugs were not included in the study. Blood samples were collected baseline at pre computed tomography (CT) and day 2, day 3 and day 7 later CT imaging. CIN was defined as either an increased serum creatinine value of 0.5 mg/dl or increased 25% to baseline. CIN frequency between groups receivingand not receiving anti-VEGF/R was compared using the chi-squared test. CIN frequency between bevacizumab and other anti-VEGF/R was also analyzed. Results There were 39 patients in the anti-VEGF/R (+) group and 53 patients in the anti-VEGF/R (-) group. Eleven patients (28%) in the anti-VEGF/R (+) group and 3 patients (5.6%) in the anti-VEGF/R (-) group had CIN (p = 0.006). In the anti-VEGF/R (+) group, 23 patients received bevacizumab (combined with FOLFOX/FOLFIRI), while 16 patients received other anti-VEGF/R (sunitinib, axitinib, regorafenib, aflibercept) effective treatments. CIN ratio in patients who received bevacizumab or other anti-VEGFR therapy was similar (p = 0 = 50). Of the patients, one patient had acute kidney injury leading to death. Conclusion CIN was significantly more frequent in cancer patients who receiving anti-VEGF/R drugs than those not receiving anti-VEGF/R drugs.en_US
dc.identifier.doi10.1007/s10147-020-01729-3
dc.identifier.endpage1762en_US
dc.identifier.issn1341-9625
dc.identifier.issn1437-7772
dc.identifier.issue10en_US
dc.identifier.pmid32591963en_US
dc.identifier.scopus2-s2.0-85087290813en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1757en_US
dc.identifier.urihttps://doi.org/10.1007/s10147-020-01729-3
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20061
dc.identifier.volume25en_US
dc.identifier.wosWOS:000543601600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofInternational Journal Of Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectContrast Mediaen_US
dc.subjectAnticancer Agentsen_US
dc.subjectSpiral CT Scanen_US
dc.subjectComputed-Tomographyen_US
dc.subjectNephrotoxicityen_US
dc.subjectRisken_US
dc.titleContrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu